High Protein Diet for Atherosclerosis
(HPA Trial)
Trial Summary
The trial excludes participants who use medications or dietary supplements that could affect the study outcomes, so you may need to stop taking certain medications. It's best to discuss your specific medications with the trial coordinators.
Research suggests that high-protein diets can help with weight loss and improve certain heart health markers like triglycerides and blood pressure. However, the overall effect on atherosclerosis risk is unclear, and some studies show that high-protein diets might worsen certain heart disease risk factors.
12345Some studies suggest that high protein diets, especially from plant sources, may reduce blood pressure and prevent cardiovascular disease. However, long-term high protein intake, particularly from animal sources, may lead to health issues like bone and kidney disorders, increased cancer risk, and progression of heart disease. It's important to consider the source of protein and consult with a healthcare provider.
678910A high protein diet, particularly one with a focus on animal protein, may differ from other treatments for atherosclerosis by potentially increasing the risk of atherosclerotic lesions, as opposed to diets rich in vegetal protein and starch which are associated with less lesion involvement. This approach contrasts with traditional dietary recommendations that emphasize reducing cholesterol and fat intake to prevent atherosclerosis.
1112131415Eligibility Criteria
This trial is for adults aged 45-75 with a BMI of 25.0 to less than 40.0 kg/m2, who do not smoke and have no significant organ dysfunction or allergies to meal ingredients. It excludes those on certain medications or supplements, highly active individuals, alcohol users with disorders, premenopausal women, prisoners, and anyone unable to consent.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive different dietary protein meals to study the impact on macrophage mTOR signaling and atherosclerosis
Follow-up
Participants are monitored for changes in monocyte p-S6 content and other cardiovascular markers